Evaluation Pembrolizumab (Keytruda): CADTH Reimbursement Suggestion: Indicator: In combination with chemotherapy, for that procedure of adult clients with domestically recurrent unresectable or metastatic triple-negative breast cancer which have not gained prior chemotherapy for metastatic ailment and whose tumours Specific programmed cell Loss of